The BMJ is an international peer reviewed medical journal and a fully “online first” publication. The BMJ’s vision is to be the world’s most influential and widely read medical journal. Our mission is to lead the debate on health and to engage, inform, and stimulate doctors, researchers, and other health professionals in ways that will improve outcomes for patients. We aim to help doctors to make better decisions.
Manage episode 300541331 series 1426075
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. James Stuart Ferriss to discuss advances and novel approaches in uterine serous cancers. Dr. Ferriss is an assistant professor in the Kelly Gynecologic Oncology division, Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine. He is the program director of the Montz fellowship in gynecologic oncology. Highlights: •Uterine serous carcinomas represent less than 10% of all uterine cancers, but 39% of disease specific deaths. •Surgery remains the cornerstone of treatment. •Our understanding of the molecular drivers of this uncommon cancer supports new, targeted therapies. •Adjuvant treatment of advanced and recurrent uterine serous carcinomas should be based on HER2 expression. • Ongoing clinical trials will further define the role of immunotherapy, WEE1 inhibitors, and PARP inhibitors in uterine serous carcinoma.